We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.11 | 4.91% | 2.35 | 2.30 | 2.40 | 2.30 | 2.20 | 2.20 | 1,317,704 | 16:35:11 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Finance Services | 0 | -3.81M | -0.0114 | -2.02 | 7.67M |
From Apr 2019 to Apr 2024
TIDMIMM
RNS Number : 5422G
Immupharma PLC
26 November 2020
RNS / eCorporate 26 November 2020
ImmuPharma PLC
("ImmuPharma" or the "Company")
Grant of Share Options & PDMR dealing
ImmuPharma PLC (LSE:IMM | Euronext Growth: ALIMM), the specialist drug discovery and development company, announces the approval of the grant of options over a total of 9,625,000 ordinary shares of 10p each in the Company ("Ordinary Shares") to Directors, employees and consultants representing 3.8% of ImmuPharma's Ordinary Shares and total voting rights (the "Options"). ImmuPharma currently has 250,221,297 Ordinary Shares in issue.
Upon the recommendation of the Company's remuneration committee, the Company has granted the Options pursuant to the Company's Share Option Plan which was adopted on 30 March 2017 (the "2017 Plan").
The exercise price for the Options is 20p being a 54% premium to the closing middle market share price of 13p on 25 November 2020. The Options will vest after three years and are exercisable between three and ten years from the date of grant.
The amount of Options granted to the Directors are summarised in the following table:
Hot Features
Premium
Director Options Granted
Dimitri Dimitriou 1,500,000
----------------
Dr Robert Zimmer 1,875,000*
----------------
Tim McCarthy 1,500,000
----------------
Dr Franco di Muzio 300,000
----------------
Dr Stephane Mery 300,000
----------------
*Includes 375,000 Options granted to Elizabeth Zimmer, Robert Zimmer's wife who is also an employee of the Company
Following the grant of Options, the Directors will have the following interests in share options in the Company:
Director Number of options Exercise Price Expiry Date
Dimitri Dimitriou 1,000,000 50.25p 30.03.2027
1,500,000 98.62p 24.11.2027
1,500,000 20.00p 26.11.2030
------------------ --------------- ------------
Dr Robert Zimmer 50,000* 90.75p 24.11.2021
100,000* 43.88p 02.06.2026
1,250,000* 50.25p 30.03.2027
1,875,000* 98.62p 24.11.2027
1,875,000* 20.00p 26.11.2030
------------------ --------------- ------------
Tim McCarthy 500,000 43.88p 02.06.2026
1,000,000 56.75p 12.07.2027
1,500,000 98.62p 24.11.2027
1,500,000 20.00p 26.11.2030
------------------ --------------- ------------
Dr Franco di 100,000 43.88p 02.06.2026
Muzio
200,000 56.75p 12.07.2027
300,000 98.62p 24.11.2027
300,000 20.00p 26.11.2030
------------------ --------------- ------------
Dr Stephane Mery 100,000 43.88p 02.06.2026
200,000 56.75p 12.07.2027
300,000 98.62p 24.11.2027
300,000 20.00p 26.11.2030
------------------ --------------- ------------
*Includes Options granted to Elizabeth Zimmer, Robert Zimmer's wife who is also an employee of the Company
The Directors currently have the following interests in Ordinary Shares:
Director Number of Ordinary % of issued share
Shares capital at
25 November 2020
Dimitri Dimitriou 3,567,430 1.45%
------------------- ------------------
Dr Robert Zimmer 27,344,514* 11.10%
------------------- ------------------
Tim McCarthy 38,462 0.01%
------------------- ------------------
Dr Franco di Muzio 99,412 0.04%
------------------- ------------------
Dr Stephane Mery 21,490 0.01%
------------------- ------------------
*includes 22,000,000 shares held by Luca & Associates AG, an entity connected with Dr Zimmer, and of which he is President and a shareholder.
Other grants of Options to Persons Discharging Managerial Responsibilities ("PDMR")
1,500,000 Options have been granted to Tim Franklin, Chief Operating Officer of the Company. Following the grant of these Options, Tim Franklin will hold Options over 1,500,000 Ordinary Shares in the Company. Similarly, 375,000 Options have been granted to Ewa Flynn, Financial Controller of the Company. Following the grant of these Options, Ewa Flynn will hold Options over 375,000 Ordinary Shares in the Company. Neither Dr Franklin nor Ewa Flynn currently hold any interests in Ordinary Shares in the Company.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dimitri Dimitriou
------------------------------- ----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position / status Chief Executive Officer
------------------------------- ----------------------------------------
b) Initial notification Initial notification
/ Amendment
------------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ImmuPharma PLC
------------------------------- ----------------------------------------
b) LEI 213800VZKGHXC7VUS895
------------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares of 10p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
------------------------------- ----------------------------------------
b) Nature of the transaction Grant of share options over Ordinary
Shares
------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price Volume
------------------------------- -------------------------- ------------
Exercise price:
20p per Ordinary
Share 1,500,000
--------------------------------------------------------------- ------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------------- ----------------------------------------
e) Date of the transaction 25 November 2020
------------------------------- ----------------------------------------
f) Place of the transaction Off market
------------------------------- ----------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Robert Zimmer
-------------------------- -------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------
a) Position / status President & Chief Scientific Officer
-------------------------- -------------------------------------------
b) Initial notification Initial notification
/ Amendment
-------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------
a) Name ImmuPharma PLC
-------------------------- -------------------------------------------
b) LEI 213800VZKGHXC7VUS895
-------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------
a) Description of the Ordinary Shares of 10p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
-------------------------- -------------------------------------------
b) Nature of the transaction Grant of share options over Ordinary
Shares
-------------------------- -------------------------------------------
c) Price(s) and volume(s) Price Volume
-------------------------- ------------------ -----------------------
Exercise price: 1,875,000
20p per Ordinary
Share
(includes 375,000
to Elizabeth Zimmer)
-------------------------- ------------------ -----------------------
d) Aggregated information N/A
- Aggregated volume
- Price
-------------------------- -------------------------------------------
e) Date of the transaction 25 November 2020
-------------------------- -------------------------------------------
f) Place of the transaction Off market
-------------------------- -------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Tim McCarthy
------------------------------- ----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position / status Non-Executive Chairman
------------------------------- ----------------------------------------
b) Initial notification Initial notification
/ Amendment
------------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ImmuPharma PLC
------------------------------- ----------------------------------------
b) LEI 213800VZKGHXC7VUS895
------------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares of 10p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
------------------------------- ----------------------------------------
b) Nature of the transaction Grant of share options over Ordinary
Shares
------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price Volume
------------------------------- -------------------------- ------------
Exercise price:
20p per Ordinary
Share 1,500,000
--------------------------------------------------------------- ------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------------- ----------------------------------------
e) Date of the transaction 25 November 2020
------------------------------- ----------------------------------------
f) Place of the transaction Off market
------------------------------- ----------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Franco Di Muzio
--------------------------------- ----------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position / status Non-Executive Director
--------------------------------- ----------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name ImmuPharma PLC
--------------------------------- ----------------------------------------
b) LEI 213800VZKGHXC7VUS895
--------------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------
a) Description of the Ordinary Shares of 10p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
--------------------------------- ----------------------------------------
b) Nature of the transaction Grant of share options over Ordinary
Shares
--------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price Volume
--------------------------------- --------------------------- -----------
Exercise price:
20p per Ordinary
Share 300,000
------------------------------------------------------------------ -----------
d) Aggregated information N/A
- Aggregated volume
- Price
--------------------------------- ----------------------------------------
e) Date of the transaction 25 November 2020
--------------------------------- ----------------------------------------
f) Place of the transaction Off market
--------------------------------- ----------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Stéphane Méry
--------------------------------- ----------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position / status Non-Executive Director
--------------------------------- ----------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name ImmuPharma PLC
--------------------------------- ----------------------------------------
b) LEI 213800VZKGHXC7VUS895
--------------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------
a) Description of the Ordinary Shares of 10p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
--------------------------------- ----------------------------------------
b) Nature of the transaction Grant of share options over Ordinary
Shares
--------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price Volume
--------------------------------- --------------------------- -----------
Exercise price:
20p per Ordinary
Share 300,000
------------------------------------------------------------------ -----------
d) Aggregated information N/A
- Aggregated volume
- Price
--------------------------------- ----------------------------------------
e) Date of the transaction 25 November 2020
--------------------------------- ----------------------------------------
f) Place of the transaction Off market
--------------------------------- ----------------------------------------
PDMR Options
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Tim Franklin
------------------------------- ----------------------------------------
2 Reason for the notification
-------------------------------------------------------------------------
a) Position / status Chief Operating Officer
------------------------------- ----------------------------------------
b) Initial notification Initial notification
/ Amendment
------------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-------------------------------------------------------------------------
a) Name ImmuPharma PLC
------------------------------- ----------------------------------------
b) LEI 213800VZKGHXC7VUS895
------------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-------------------------------------------------------------------------
a) Description of the Ordinary Shares of 10p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
------------------------------- ----------------------------------------
b) Nature of the transaction Grant of share options over Ordinary
Shares
------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price Volume
------------------------------- -------------------------- ------------
Exercise price:
20p per Ordinary
Share 1,500,000
--------------------------------------------------------------- ------------
d) Aggregated information N/A
- Aggregated volume
- Price
------------------------------- ----------------------------------------
e) Date of the transaction 25 November 2020
------------------------------- ----------------------------------------
f) Place of the transaction Off market
------------------------------- ----------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Ewa Flynn
--------------------------------- ----------------------------------------
2 Reason for the notification
---------------------------------------------------------------------------
a) Position / status Financial Controller
--------------------------------- ----------------------------------------
b) Initial notification Initial notification
/ Amendment
--------------------------------- ----------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------------
a) Name ImmuPharma PLC
--------------------------------- ----------------------------------------
b) LEI 213800VZKGHXC7VUS895
--------------------------------- ----------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---------------------------------------------------------------------------
a) Description of the Ordinary Shares of 10p each
financial instrument
, type of instrument
ISIN: GB0033711010
Identification code
--------------------------------- ----------------------------------------
b) Nature of the transaction Grant of share options over Ordinary
Shares
--------------------------------- ----------------------------------------
c) Price(s) and volume(s) Price Volume
--------------------------------- --------------------------- -----------
Exercise price:
20p per Ordinary
Share 375,000
------------------------------------------------------------------ -----------
d) Aggregated information N/A
- Aggregated volume
- Price
--------------------------------- ----------------------------------------
e) Date of the transaction 25 November 2020
--------------------------------- ----------------------------------------
f) Place of the transaction Off market
--------------------------------- ----------------------------------------
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
ImmuPharma PLC ( www.immupharma.com )
Tim McCarthy, Chairman + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin
Stanford Capital Partners (Joint Broker) +44 (0) 203 36 8 3550
Patrick Claridge
John Howes
Bob Pountney +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
4Reliance (Euronext Growth Listing Sponsor) +32 (0) 2 747 02 60
Jean-Charles Snoy
Degroof Petercam (Liquidity Provider) +32 (0) 2 287 95 34
Erik De Clippel
Backstage Communication
Olivier Duquaine +32 (0) 477 504 784
Gunther De Backer +32 (0) 475 903 909
Notes to Editors
About ImmuPharma PLC
ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, anti-infectives, metabolic diseases and cancer. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase III for the treatment of systemic lupus erythematosus (lupus / SLE). Lupus is an autoimmune disease which if left untreated can be fatal. Preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase III trial for Lupuzor(TM) and commercialise in the US.
For additional information about ImmuPharma please visit www.immupharma.com .
ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHUVOWRRAUAUAA
(END) Dow Jones Newswires
November 26, 2020 02:00 ET (07:00 GMT)
1 Year Immupharma Chart |
1 Month Immupharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
